Nov 13, 2019
MediSieve as a Winner of Beanstalks Competition 2019
Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical or Healthcare Device Award’ in the Beanstalks competition 2019.
LONDON – November 13, 2019 – Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical or Healthcare Device Award’ in the Beanstalks competition 2019.
Dr George Frodsham, founder and CEO of MediSieve said, “We were very pleased to receive this award in what was a very competitive line-up, which included some fantastic and innovative companies.”
The final round of 2019 Beanstalks took place at the GIANT Health Event, held at the Chelsea Football Club Stadium in October 2019 where MediSieve beat off tough competition against GyroGear and Quantune.
Dr Frodsham continued, “The event was a good opportunity for us to continue spreading the word about MediSieve to help raise awareness of the company and the work we’re doing. Thank to you GIANT for the opportunity.”
GIANT Health is one of London’s major healthcare events. It was the second time that MediSieve received an award in this prestigious competition. Two years ago, they won CMS Healthcare Startup of the Year.
This latest accolade reflects MediSieve’s diligent work and steady growth. Dr Frodsham was recently awarded the BBSRC Innovator of the Year Award whilst MediSieve’s chief technology officer, Cristina Blanco-Andujar, completed the Royal Academy of Engineering's prestigious SME Leaders Programme. In October 2019, MediSieve was also a finalist of Emerging Technologies, which was run by the Royal Society of Chemistry.
As winners of the competition, MediSieve will receive a multitude of prizes to help grow and develop the business even further, including, free consultancy and strategy healthchecks.
Beanstalks celebrates the advances within the medical sector. With a primary focus on startup companies, the competition looks at revolutionary healthcare solutions, ranging from ideas in the seed, to end products. The award provides support to aspiring entrepreneurs who aim at tackling the world’s most dreadful health conditions.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: